Rong Zhou

发表

Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients: A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE Studies

J. Kastelein, M. Bots, C. Ballantyne, 2010, Circulation. Cardiovascular imaging.

Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.

E. Stein, A. Elis, Rong Zhou, 2011, The American journal of cardiology.

Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study (ACADEMIC)

Q. Ji, Weiguo Gao, Rong Zhou, 2022, Diabetes, obesity & metabolism.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia

J. Kastelein, D. Orloff, R. Vige, 2016, Cardiology.

Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades

E. Stein, A. Elis, Rong Zhou, 2013, Cardiology in the Young.

Accurate Assessment of LDL Cholesterol Reduction at Levels below 70 mg / dL has Implications in the Estimation of Efficacy for New Drugs in Development

E. Stein, Rong Zhou, Christine Fritz, 2015 .

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

J. Kastelein, D. Orloff, R. Vige, 2016, Journal of clinical lipidology.

Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

J. Després, J. Kastelein, D. O'leary, 2011, Heart.

Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

E. Stein, D. Kereiakes, H. Bays, 2019, Atherosclerosis.

FRIEDEWALD FORMULA SIGNIFICANTLY UNDERESTIMATES LDL CHOLESTEROL COMPARED TO PREPARATIVE ULTRACENTRIFUGATION BELOW 70 MG/DL LEADING TO OVERESTIMATION OF THE LDL CHOLESTEROL REDUCTION FOR NEW DRUGS IN DEVELOPMENT

E. Stein, Rong Zhou, Christine Fritz, 2014 .

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.

R. Taub, G. Hovingh, J. Kastelein, 2022, Journal of the American College of Cardiology.

The association between CD14 gene C-260T polymorphism and coronary heart disease risk: a meta-analysis

Rong Zhou, Dongming Zhang, Yan Liu, 2012, Molecular Biology Reports.

Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study

E. Stein, D. Kereiakes, Rong Zhou, 2019 .

LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY

E. Stein, Rong Zhou, T. Turner, 2019, Journal of the American College of Cardiology.